Investigational Drug Information for TAK-925
What is the drug development status for TAK-925?
TAK-925 is an investigational drug.
There have been 8 clinical trials for TAK-925.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 3rd 2023.
The most common disease conditions in clinical trials are Sleep Apnea Syndromes, Apnea, and Sleep Apnea, Obstructive. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and [disabled in preview].
There are thirty-four US patents protecting this investigational drug and forty-six international patents.
Summary for TAK-925
| US Patents | 34 |
| International Patents | 46 |
| US Patent Applications | 80 |
| WIPO Patent Applications | 38 |
| Japanese Patent Applications | 18 |
| Clinical Trial Progress | Phase 1 (2023-05-03) |
| Vendors | 25 |
Recent Clinical Trials for TAK-925
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery | Takeda | Phase 2 |
| A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea | Takeda | Phase 1 |
| A Study of Danavorexton in Anesthetized Adults | Takeda | Phase 1 |
Clinical Trial Summary for TAK-925
Top disease conditions for TAK-925
Top clinical trial sponsors for TAK-925
US Patents for TAK-925
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TAK-925 | ⤷ Start Trial | Organic layer composition, organic layer, and method of forming patterns | Samsung SDI Co Ltd | ⤷ Start Trial |
| TAK-925 | ⤷ Start Trial | Substituted piperidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka, JP) | ⤷ Start Trial |
| TAK-925 | ⤷ Start Trial | Dispersion liquid used for forming porous film, porous film, power storage element, and method for producing porous film | Tokyo Ohka Kogyo Co Ltd | ⤷ Start Trial |
| TAK-925 | ⤷ Start Trial | Regenerated oxidized celulose based hemostatic materialcontaining antifibrolytic agents | Individual | ⤷ Start Trial |
| TAK-925 | ⤷ Start Trial | Substituted piperidine compound and use thereof | Takeda Pharmaceutical Co Ltd | ⤷ Start Trial |
| TAK-925 | ⤷ Start Trial | Process for the preparation of N-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereof | MSN Laboratories Pvt Ltd | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TAK-925
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TAK-925 | Argentina | AR107519 | 2036-02-04 | ⤷ Start Trial |
| TAK-925 | Australia | AU2017215021 | 2036-02-04 | ⤷ Start Trial |
| TAK-925 | Brazil | BR112018015574 | 2036-02-04 | ⤷ Start Trial |
| TAK-925 | Canada | CA3013428 | 2036-02-04 | ⤷ Start Trial |
| TAK-925 | Chile | CL2018002099 | 2036-02-04 | ⤷ Start Trial |
| TAK-925 | China | CN108884043 | 2036-02-04 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
